Andrew Beggs, Samson Gamgee Chair of Surgery at University of Birmingham, shared on LinkedIn:
“I’m delighted to be contributing to STRIDE-RCT, a NIHR (National Institute for Health and Care Research) and Office for Life Sciences co-funded project looking at Multi-Cancer Early Detection (MCED), co-lead by Aneel Bhangu and Dmitri Nepogodiev here at the University of Birmingham.
STRIDE sets out to improve the conversion rate of patients presenting with symptoms or signs of cancer in the abdomen. It will provide a cluster randomised platform to explore MCED to assist with triage, reducing pressure on diagnostics like colonoscopy or CT scanning.
As it’s a platform, multiple MCEDs will be trialed, and we are working within it to bring our labs expertise in the science and technology of MCEDs to patients.
Hopefully it will find a more effective way to utilize MCEDs and improve the patient journey of those with cancer.
Here’s the excellent article by Eleanor Hayward.”
Additional information on STRIDE-RCT
- The University of Birmingham is launching STRIDE-RCT, a world-first clinical trial across at least 200 GP practices in England, involving more than 20,000 NHS patients to evaluate blood tests for earlier cancer detection.
- The trial will assess blood tests capable of detecting multiple cancers from a single sample, including pancreatic, ovarian, bowel, stomach, liver, prostate, kidney, and other cancers.
- Patients aged 45 and older presenting with abdominal symptoms, such as persistent bloating or discomfort, will be offered participation. Tests will use artificial intelligence and blood protein analysis to identify early cancer markers.
- Funded with up to £8.49 million through the NIHR, the trial will evaluate blood tests alongside GPs’ clinical judgement to determine whether they can improve early diagnosis before potential nationwide implementation.
You may also be interested in:
Cameron Wells: Association of Surgical Ward Nurse Staffing With Postoperative Failure to Rescue
Natera’s Multi-Cancer Early Detection Test Receives FDA Breakthrough Device Designation